Abstract
Melanoma is rapidly evolving because of advances in noninvasive diagnosis, targeted therapies, and improved prognostic methods. This article discusses what is new in melanoma risk factors, prevention, clinical management, and targeted treatment. The incidence continues to increase worldwide, whereas mortality is steadily improving. This trend reinforces the importance of dermatologists comprehensively understanding all aspects of melanoma. Further research is needed to continue making a material impact on outcomes for patients.
Keywords:
Diagnosis; Genomics; Management; Melanoma epidemiology; Prognosis; Risk factors.
Copyright © 2018 Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Biopsy
-
Coffee
-
Dermatologic Surgical Procedures*
-
Dielectric Spectroscopy
-
Early Detection of Cancer
-
Genetic Predisposition to Disease
-
Genomics
-
Humans
-
Inflammatory Bowel Diseases / epidemiology
-
Ipilimumab / therapeutic use
-
Melanoma / diagnosis
-
Melanoma / epidemiology
-
Melanoma / genetics
-
Melanoma / therapy*
-
Microscopy, Confocal
-
Nivolumab / therapeutic use
-
Phosphodiesterase 5 Inhibitors / therapeutic use
-
Primary Prevention
-
Prognosis
-
Protective Factors
-
Risk Factors
-
Secondary Prevention
-
Sentinel Lymph Node Biopsy
-
Sun Protection Factor
-
Sunscreening Agents / therapeutic use
-
Ultrasonography
-
Vemurafenib / therapeutic use
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Coffee
-
Ipilimumab
-
Phosphodiesterase 5 Inhibitors
-
Sunscreening Agents
-
Vemurafenib
-
Nivolumab
-
pembrolizumab